The use of stem cells for regenerating damaged heart tissue offers great potential, but many technical questions remain. Understanding which cell types are most beneficial and how they should be employed is a central issue. Several clinical trials involving stem cells were presented at AHA. Two were of particular interest. SCIPIO, a phase I clinical trial, is the first to assess the effectiveness of cardiac stem cells (CSCs) for treating ischemic heart failure. Dr.